Information Provided By: 
Fly News Breaks for November 9, 2015
CNCE, PBYI, PRTA, INSM
Nov 9, 2015 | 05:57 EDT
UBS analyst Matthew Roden downgraded Insmed (INSM) to Neutral citing the company's "negative" update to the enrollment progress for the Arikayce Phase 3 study in Nontuberculous Mycobacteria. The drug is now a 2017 story, Roden tells investors in a research note. He cut his price target for shares to $18 from $35 and views Prothena (PTRA), Puma Biotechnology (PBYI) and Concert Pharmaceuticals (CNCE) as more attractive clinical-stage biotech opportunities. Insmed closed Friday down $2.77 to $17.09.
News For INSM;PRTA;PBYI;CNCE From the Last 2 Days
